Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24261
Title: A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Adult,Aged,Antineoplastic Agents/adverse effects/therapeutic use,Antineoplastic Agents, Alkylating/adverse effects/therapeutic use,Antineoplastic Agents, Phytogenic/adverse effects/therapeutic use,Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use,Carcinoma, Non-Small-Cell Lung/*drug therapy,Cisplatin/adverse effects/therapeutic use,Etoposide/adverse effects/therapeutic use,Female,Humans,Ifosfamide/adverse effects/therapeutic use,Lung Neoplasms/*drug therapy,Male,Middle Aged,Prognosis,Prospective Studies,Survival Rate,Vinblastine/adverse effects/therapeutic use
URI: https://olympias.lib.uoi.gr/jspui/handle/123456789/24261
ISSN: 0923-7534
Link: http://www.ncbi.nlm.nih.gov/pubmed/8839908
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Pavlidis-1996-a prospective randomized.pdf1.48 MBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons